Ultrasound Guided Radiofrequency Ablation of the Occipital Nerve

August 30, 2024 updated by: Timothy Sowder, MD, University of Kansas Medical Center
Study an ultrasound guided approach to radiofrequency ablation of the occipital nerve that makes it possible to see the needle during treatment procedure. It is hoped this will reduce the amount of pain after the standard of care procedure.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients between the ages of 18-80 with a diagnosis of occipital neuralgia or migraine overlying the occipital region.
  • A diagnosis of occipital neuralgia will be based on the International Classification of Headache Disorders (ICHD), whose criteria include: paroxysmal stabbing pain in the distribution of the GON, tenderness over the affected nerve, and relief of pain for at least 3 hours after bupivacaine local anesthetic block of the affected nerve.
  • Patients may also be included if they have a diagnosis of migraine based on the ICHD criteria with predominance of pain over the occipital region that responded to occipital nerve block.
  • Patients must have failed oral medications including NSAIDs, opioids, and anticonvulsants for the management of their pain.
  • Failed treatment will be <50% pain reduction with oral medication.
  • Patients must report headache frequency of at least 10 days per month.

Exclusion Criteria:

  • Patients will be excluded from the trial if they have an unstable medical or psychological condition,
  • are pregnant,
  • have an implanted cardiac pacemaker or defibrillator that could not be disabled,
  • have had a craniotomy or scar tissue overlying the site from a previous surgery,
  • have a history of cervical spine fusion,
  • have evidence of elevated ICP or intracranial tumor,
  • or have previous RFA treatment of the greater or lesser occipital nerve.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction pain scores reported using an 11-point numeric rating scale (NRS)
Time Frame: 18 Months
Pain scores will be assessed 0-10 at the beginning of the study and at the end. We will compare mean pain scores pre-intervention and post-intervention, and we expect mean pain scores will decrease by 4 points on the NRS
18 Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of headache days
Time Frame: 18 months
We will compare frequency of headache days pre-intervention and post-intervention
18 months
Frequency of moderate-severe headaches
Time Frame: 18 months
We will compare frequency of moderate-severe headaches days pre-intervention and post-intervention
18 months
Use of acute pain medications
Time Frame: 18 Months
We will compare frequency of Use of acute pain medications pre-intervention and post-intervention
18 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2022

Primary Completion (Estimated)

December 30, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

August 30, 2024

First Submitted That Met QC Criteria

August 30, 2024

First Posted (Actual)

September 3, 2024

Study Record Updates

Last Update Posted (Actual)

September 3, 2024

Last Update Submitted That Met QC Criteria

August 30, 2024

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nerve Pain

3
Subscribe